|
Gene Therapy to Improve Wound Healing in Patients With Diabetes Clinical Trials Info presented on Clinical Trials Search is not intended to be a substitute for certified medical advice, visits or professional assistance using a real physician. We are not physicians. Always consult your dr. about Gene Therapy to Improve Wound Healing in Patients With Diabetes conditions. Clinical Trials Search.org is a site dedicated to listing clinical research studies in human subjects. Gene Therapy to Improve Wound Healing in Patients With Diabetes Clinical research trials and Gene Therapy to Improve Wound Healing in Patients With Diabetes health trials happen in many of localities throughout the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically measure the effectualness of new drugs. The function of the studies / projects is to resolve particular human medical questions. Clinical trials are a popular manner for mDs, government agencies, and private sector corporations to discover remedies for all varieties of circumstances, like Gene Therapy to Improve Wound Healing in Patients With Diabetes. Gene Therapy to Improve Wound Healing in Patients With Diabetes Clinical Trials and other clinical trials allow volunteers to obtain healthcare treatment options before they are available to the masses. Some times the participants undergo professional assistance for free of charge, and occasionally they are paid for their time. Sometimes there is a cost for a Gene Therapy to Improve Wound Healing in Patients With Diabetes clinical trial. Human subjects often get the best healthcare available for their Gene Therapy to Improve Wound Healing in Patients With Diabetes condition. Dangers are a reality, however, and may include additional or frequent mD visits, healthcare dangers (potentially life-jeopardising), and/or the treatment being ineffectual. Trials are federally governed with rigorous guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "G" Clinical Trials Conditions > Gene Therapy to Improve Wound Healing in Patients With Diabetes  Gene Therapy to Improve Wound Healing in Patients With Diabetes
Gene Therapy to Improve Wound Healing in Patients With Diabetes
For Condition: Foot wounds,Diabetes,Diabetic Foot Ulcers,Wounds and Injuries
Status: Recruiting
Sponsor(s): Selective Genetics, Inc. ,
Synopsis: Patients with diabetes may develop chronic wounds that respond poorly to treatment. Gene therapy with the platelet-derived growth factor-B gene has been shown to help with the healing of chronic wounds. This study will evaluate a new way to deliver the gene to the wound tissue.
Details: Chronic wounds, such as diabetic ulcers, pressure ulcers, and venous stasis ulcers, cause significant morbidity in millions of patients each year in the United States. Individuals with long-standing diabetes develop both peripheral vascular disease and peripheral neuropathy. These patients may not feel pressure from shoes or objects which can damage their skin. Once a wound is formed, it may heal very slowly or not at all due to diabetic complications. Platelet-derived growth factor-B (PDGF-B) has been approved for use in diabetic ulcers. However, delivery and maintenance of the drug at the wound site in sufficient quantities for a sufficient period of time is a major hurdle to widespread use. Gene activated matrix (GAM) technology offers the opportunity to place a therapeutic gene contained within a structural matrix into a wound site. This study will evaluate the safety and potential clinical utility of topical applications of GAM501, a gene for PDGF-B contained within an E1-deleted adenoviral vector and formulated in a bovine type I collagen gel. This formulation allows for the migration of wound repair cells into the structural matrix, where they encounter the viral vector and subsequently produce the therapeutic protein within the local wound environment. Participants in this study will receive up to four treatments with GAM501. Participants will be followed by multiple observations over a 6 to 7 month period.
Eligibility:
Study Type: Interventional, Treatment, Non-Randomized, Open Label, Dose Comparison, Factorial Assignment, Safety Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria - Adequately controlled diabetes mellitus (type I or II) as defined by HbA1c < 10.0% - Cutaneous, lower extremity, plantar medial or lateral surface ulcer between 1 and 10 cm2 post-debridement - Ulcer present for > 6 weeks prior to study entry - Ulcer free of all necrotic and infected soft tissue - Affected limb transcutaneous oxygen pressure (TcpO2) > 30 mmHg at screening or a palpable dorsal pedal or posterior tibial pulse - Inability to perceive 10 grams pressure using a Semmes-Weinstein 5.07 monofilament in the peri-ulcer area
Total Enrollment: 21
Location and Contact Information:
Overall Study Official:
BarbaraSosnowski, Study Director, Selective Genetics, Inc.
Foot and Ankle Medical Center *Recruiting*
Phoenix, Arizona, 85015
United States
Recruiting Arthur Tallis 602-274-4100
University of California, San Diego *Recruiting*
San Diego, California, 92103
United States
Recruiting Analyn Dolopo 619-543-7341
Additional Information:
Study ID Numbers: NIAMS-093; R44 AR46154
Study Start Date: August 2002
Record last reviewed: March 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00065663
Other Diabetes Studies:
1. Gene Therapy to Improve Wound Healing in Patients With Diabetes
2. Prevention of Violent Behavior Among Children
Related Studies:
Other Diabetes Clinical Trials
Other California Clinical Trials
Other San Diego Clinical Trials
Gene Therapy to Improve Wound Healing in Patients With Diabetes
|
|
|
|
|
|
|
|
